Edition:
United States

Consort Medical PLC (CSRT.L)

CSRT.L on London Stock Exchange

1,011.00GBp
11:35am EDT
Change (% chg)

1.00p (+0.10%)
Prev Close
1,010.00p
Open
1,011.00p
Day's High
1,030.00p
Day's Low
1,011.00p
Volume
6,884
Avg. Vol
54,010
52-wk High
1,155.00p
52-wk Low
904.20p

Summary

Name Age Since Current Position

Peter Fellner

72 2009 Non-Executive Independent Chairman of the Board

Jonathan Glenn

46 2007 Chief Executive, Executive Director

Richard Cotton

55 2012 Chief Financial Officer, Executive Director

John Ilett

2015 Group General Counsel, Company Secretary

Keyvan Djamarani

Managing Director, Bespak

Ian Muir

Managing Director, Aesica

Steve Crummett

50 2012 Non-Executive Director

Maria Ginman-Jones

2015 Non-Executive Director

Andrew Joseph Hosty

50 2014 Non-Executive Director

Ian Nicholson

54 2012 Non-Executive Director

William Jenkins

67 2011 Senior Non-Executive Independent Director

Biographies

Name Description

Peter Fellner

Dr. Peter Fellner is Non-Executive Independent Chairman of the Board of Consort Medical Plc., since May 2009.He is currently Chairman of Vernalis plc, Optos plc, and Ablynx nv. He is also a member of the Novo A/S Advisory Group. He previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. More recently he served as Chairman of Biotie Therapies Corp. from 2010 to 2014, and as Chairman of Acambis plc from 2006, until its acquisition by Sanofi Aventis in 2008, and as Chairman of Premier Research Group plc from 2007 to 2008, when it was acquired by a private-equity backed group. In addition, he was Vice Chairman of Astex Pharmaceuticals, Inc from 2011 to 2013 and a director of the global biopharmaceutical company UCB SA from 2005 to April 2014. He also served as a director of QinetiQ Group plc and Evotec AG. Dr Fellner has many years’ experience in the pharmaceutical and biotechnology industry in a variety of roles including research and development and senior executive and non-executive positions.

Jonathan Glenn

Mr. Jonathan Glenn is Chief Executive, Executive Director of Consort Medical plc. He was appointed Chief Executive in December 2007 and before that had been Group Finance Director since September 2006. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. He is a member of the Institute of Chartered Accountants in England and Wales.

Richard Cotton

Mr. Richard Cotton is no longer as Chief Financial Officer, Executive Director of Consort Medical Plc., with effect from December 2016. He is a Chartered Management Accountant, has been appointed Group Finance Director of Consort Medical with effect from 25 June 2012. From 2008 to 2011 he was Group Finance Director of Vitec Group plc, from 2005 to 2008 Group Finance Director at Wagon plc (Wagon plc entered administration on 10th December 2008), and from 2001 to 2005 Group Finance Director of McLeod Russell plc.

John Ilett

Mr. John W. Ilett has been appointed as Group General Counsel and Company Secretary of the Company, with effect from 3 November 2015. John has over 20 years of experience in the pharmaceutical/life sciences sector and brings a wealth of experience to the position from previous senior legal roles. These include at LGC Group Limited where he was General Counsel and Company Secretary from 2010 to 2015, and senior legal roles at Biomarin Pharmaceutical, Inc., Cephalon, Inc., Oxford Glycosciences plc and British Biotech plc. John also worked in private practice for several years at Stringer Saul (now Faskens). John is a qualified solicitor.

Keyvan Djamarani

Dr Keyvan Djamarani serves as Managing Director, Bespak of the Company. He has over 15 years of experience at Consort Medical having previously held general management roles at Bespak Europe in the UK and Bespak Inc. in the US as well as a short appointment at Kings Systems Inc. prior to its disposal in 2013. Previously Keyvan held various project and production management roles at Unilever UK’s Detergents & Household Products and Personal Products Divisions.

Ian Muir

Dr Ian Muir serves as Managing Director, Aesica of the Company. Mr. Ian holds a PhD in Pharmaceutical Science and has over 20 years’ experience in the pharmaceutical industry working for Wyeth, Mayne Pharma and BMS in Europe, the US and Australia, with significant senior operational and commercial experience over the past ten years in contract manufacturing roles for RP Scherer, Cardinal Health and Catalent where he has been responsible for leading both R&D activities and commercial manufacturing operations. In Ian’s most recent role prior to joining Aesica, he was responsible for the global provision of contract development and manufacturing services of oral dose forms.

Steve Crummett

Mr. Steve Crummett has been appointed as Non-Executive Director of Consort Medical PLC., with effect from 13 June 2012. is Group Finance Director of Filtrona plc, a FTSE 250 company, having been appointed to the role in 2008. Previously Steve was Group Finance Director of Filtrona plc (now Essentra plc) from 2008 to 2012. From 2003 to 2006 Steve was Group Director, Mergers & Acquisitions at Exel plc and previously held senior finance roles with McKechnie plc and Logica plc. Mr Crummett is a Chartered Accountant

Maria Ginman-Jones

Ms. Maria Charlotta Ginman-Jones (known as Ms Charlotta Ginman) has been appointed as Non-Executive Director of Consort Medical Plc., with effect from 11 February 2015. Ms Ginman qualified as a Chartered Accountant at Ernst & Young before spending a career in investment banking and commercial organisations, principally in technology-related businesses. Ms Ginman began her career at Ernst & Young joining in 1989, and was then appointed to a series of senior roles in investment banking with JP Morgan, Deutsche Bank and UBS both in London and Singapore. Ms Ginman has also held senior roles within Nokia Corporation, including acting as Chief Financial Officer of its luxury mobile phone division Vertu Corporation Limited. Ms Ginman oversaw the successful sale of Vertu Corporation to a private equity group in 2012. Until 21 August 2014 Ms Ginman was a non-executive director of Wolfson Microelectronics plc. Ms Ginman is a Non-executive Director of Kromek Group plc, where she is the current Chairman of the Audit Committee, and is also a Non-executive Director of Pacific Assets Trust plc and Polar Capital Technology Trust plc.

Andrew Joseph Hosty

Mr. Andrew Hosty is a Non-Executive Director of the Company. Andrew Hosty is Chief Operating Officer at Morgan Advanced Materials plc, an appointment he has held since February 2013. Prior to this Andrew was Chief Executive Officer of Morgan Ceramics and joined the Morgan Advanced Materials plc Board in July 2010. Before this he held a number of senior positions within Morgan Advanced Materials. Andrew is also a non executive director of British Ceramic Research Limited. Previously Andrew was a non executive director of Fiberweb plc from 2012 to 2013 and President of the British Ceramics confederation from 2003 to 2005.

Ian Nicholson

Mr. Ian Nicholson has been appointed as Non-Executive Director of Consort Medical PLC., with effect from 13 June 2012. He has been Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company since 2004. He is Chairman of Bioventix Ltd, a diagnostics company, and a Non-executive Director of Symphogen A/S, an antibody therapeutics company. From 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's biotechnology company. He has experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US.

William Jenkins

Dr. William J. Jenkins, M.D., has been appointed as Senior Non-Executive Independent Director of Consort Medical plc with effect from 1 September 2011. He is a non-executive director of Ablynx nv, Allecra Therapeutics GmbH and AlloCyte Pharmaceuticals AG. He is also an ad hoc member of the board of Evotec AG and a member of their Scientific Advisory Board as well as a member of the Scientific Advisory Board of BB Biotech Ventures and a member of the Strategic Advisory Board of Chiesi Farmaceutici SpA. He is principal of William Jenkins Pharma Consulting.